Drug Profile
Research programme: aurora kinase inhibitors - Bristol-Myers Squibb/Daiichi Sankyo
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Daiichi Sankyo Company
- Class Small molecules
- Mechanism of Action Aurora kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 10 Nov 2014 Ambit Biosciences Corporation has been acquired by Daiichi Sankyo Company
- 09 Nov 2007 Ambit Biosciences and Bristol-Myers Squibb expand their drug discovery collaboration for kinase inhibitors